CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.72B, above the global median of $1.15B
- PositionDebt-to-equity is 21.76×, higher than 95% of its Biotechnology peers (median 0.1×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.72BUSDvs all stocks (USD)
Revenue (TTM)
232.39MUSDvs all stocks (USD)
Profit Margin
-11.53%vs Biotechnology peers
Beta
0.3790xvs all stocks
52-Week Change
232.45%vs all stocks
Market Capitalization
1.72BUSDvs all stocks (USD)
Enterprise Value
1.62BUSDvs all stocks (USD)
Forward P/E
10.34xvs Biotechnology peers
Price to Sales (TTM)
6.90xvs Biotechnology peers
Price to Book (MRQ)
123.35xvs Biotechnology peers
Enterprise to Revenue
6.95xvs Biotechnology peers
Enterprise to EBITDA
39.07xvs Biotechnology peers
Profit Margin
-11.53%vs Biotechnology peers
Operating Margin
-135.53%vs Biotechnology peers
Return on Assets (TTM)
6.78%vs Biotechnology peers
Return on Equity (TTM)
-114.55%vs Biotechnology peers
Revenue (TTM)
232.39MUSDvs all stocks (USD)
Revenue per Share (TTM)
8.22USDUpdated Jul 18, 2026Quarterly Revenue Growth
-8.00%vs Biotechnology peers
Gross Profit (TTM)
103.61MUSDvs all stocks (USD)
EBITDA (TTM)
69.25MUSDvs all stocks (USD)
Net Income (TTM)
-26.79MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.98%vs Biotechnology peers
Operating Cash Flow (TTM)
4.48MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
8.32MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
234.60MUSDFY2025 · Dec 31, 2025Operating Income
47.90MUSDvs all stocks (USD)
Pre-tax Income
-13.07MUSDFY2025 · Dec 31, 2025Income Tax Expense
164.00KUSDFY2025 · Dec 31, 2025Net Income
-13.23MUSDFY2025 · Dec 31, 2025EBIT
66.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
69.25MUSDFY2025 · Dec 31, 2025Research & Development
135.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
50.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
79.89MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
28.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-13.23MUSDFY2025 · Dec 31, 2025Operating Cash Flow
22.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
22.73MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.42M of depreciation against 87K of capital expenditure, and its own free-cash-flow line reads 19.61M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
238.20MUSDFY2025 · Dec 31, 2025Income Tax Paid
78.00KUSDFY2025 · Dec 31, 2025Interest Paid
79.99MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-13.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.42MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
79.89MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.92MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-87.33MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.93MUSDFY2025 · Dec 31, 2025Capital Expenditures
-87.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-196.41MUSDFY2025 · Dec 31, 2025Sale of Investments
424.53MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
228.03MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-68.63MUSDFY2025 · Dec 31, 2025Other Financing Charges
-76.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-131.16MUSDFY2025 · Dec 31, 2025Shares Outstanding
29.03MSharesUpdated Jul 18, 2026Float Shares
19.79MSharesUpdated Jul 18, 2026Shares Short
5.15MSharesUpdated Jul 18, 2026Short Ratio
8.59daysvs all stocks
Short % of Shares Outstanding
38.70%vs all stocks
% Held by Insiders
5.68%vs all stocks
% Held by Institutions
101.74%vs all stocks
Total Cash (MRQ)
286.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.84USDUpdated Jul 18, 2026Total Debt (MRQ)
277.36MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
21.76xvs Biotechnology peers
Current Ratio (MRQ)
7.58xvs Biotechnology peers
Book Value per Share (MRQ)
0.4390USDUpdated Jul 18, 2026Total Assets
364.39MUSDvs all stocks (USD)
Total Current Assets
350.25MUSDFY2025 · Dec 31, 2025Total Liabilities
327.19MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.14MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
288.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.63MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
238.20MUSDFY2025 · Dec 31, 2025Other Short-term Investments
73.44MUSDFY2025 · Dec 31, 2025Accounts Receivable
33.85MUSDFY2025 · Dec 31, 2025Accounts Payable
3.87MUSDFY2025 · Dec 31, 2025Short-term Debt
2.08MUSDFY2025 · Dec 31, 2025Long-term Debt
12.03MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
276.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-772.56MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
37.21MUSDvs all stocks (USD)
52-Week Low
11.40USDUpdated Jul 18, 202652-Week High
72.36USDUpdated Jul 18, 202652-Week Change
232.45%vs all stocks
Beta
0.3790xvs all stocks
50-Day MA
60.49USDUpdated Jul 18, 2026200-Day MA
40.22USDUpdated Jul 18, 2026Avg 10-Day Volume
799.29KSharesUpdated Jul 18, 2026Avg 30-Day Volume
660.35KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.02USDUpdated Jul 18, 2026Other Income / Expense
5.43MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 21.76×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 21.76Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 123.35×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 123.349Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 286,455,008Total Debt (USD): 277,355,008Debt-to-Equity: 21.76
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.04Revenue Growth YoY: -0.08
Financial Health
Altman Z-Score 2.46: grey zoneSignificant
Altman Z-Score: 2.46
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.72B, above the global median of $1.15BNotable
Market cap (USD): 1,717,291,898Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MoonLake Immunotherapeutics
Tier 1ProductionApproval-Gated PipelineRuleRisk
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk